Cleveland BioLabs radiation drug ready for potential Japan use

Although Cleveland BioLabs has yet to receive FDA approval for its irradiation treatment CBLB502, or Protectan, the fast-tracked, orphan drug may be made available for Japanese workers who have been exposed to lethal amounts of radiation. According to Rachel Levine, Director of Corporate Development and Communications at Cleveland BioLabs, hundreds of thousands of doses are are available if the drug is OKed for emergency use. "We are ready to assist," she said to Benzinga. "It is in the hands of the appropriate agencies, if they feel it is appropriate to use the drug." Article | Item

Suggested Articles

MicuRx nabbed $7.78 million from a nonprofit focused on antimicrobial resistance to push its third antimicrobial program into human trials.

The FDA has placed a phase 1/2 trial of Passage Bio’s GM1 gene therapy on clinical hold pending further assessment of the risk of its delivery device.

Danish drugmaker Novo Nordisk is opening up its bleeding disorder trials five months after they were stopped.